These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38195816)

  • 1. Multidimensional Transcriptomics Unveils RNF34 as a Prognostic Biomarker and Potential Indicator of Chemotherapy Sensitivity in Wilms' Tumour.
    Zheng J; Liu F; Tuo J; Chen S; Su J; Ou X; Ding M; Chen H; Shi B; Li Y; Chen X; Wang C; Su C
    Mol Biotechnol; 2024 May; 66(5):1132-1143. PubMed ID: 38195816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics Analysis of the Expression and Prognostic Value of PLAU Gene in Wilms' Tumor.
    Li D; Ding C; Huang F; Chang M; Lu Z; Li G; Li Y; Gao H; Sun F
    Anticancer Res; 2024 Sep; 44(9):3829-3842. PubMed ID: 39197889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
    Cheah PL; Looi LM; Chan LL
    Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Elevated Cholesterol Synthesis as a Prognostic Marker in Wilms' Tumor: A Bioinformatic Analysis.
    He Y; Cui X; Lin Y; Wang Y; Wu D; Fang Y
    Biomed Res Int; 2021; 2021():8826286. PubMed ID: 33628817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of promoter hypomethylation and expression of p73 as a diagnostic and prognostic biomarker in Wilms' tumour.
    Song D; Yue L; Wu G; Ma S; Yang H; Liu Q; Zhang D; Xia Z; Jia J; Wang J
    J Clin Pathol; 2016 Jan; 69(1):12-8. PubMed ID: 26184366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
    Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
    Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of lncRNA-Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms' Tumor.
    Zheng H; Li BH; Liu C; Jia L; Liu FT
    Biomed Res Int; 2020; 2020():4951692. PubMed ID: 32149111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.
    Pode-Shakked N; Metsuyanim S; Rom-Gross E; Mor Y; Fridman E; Goldstein I; Amariglio N; Rechavi G; Keshet G; Dekel B
    J Cell Mol Med; 2009 Aug; 13(8B):1792-1808. PubMed ID: 20187302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
    Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
    Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Wilms' tumour. Current recommendations.
    Mehta MP; Bastin KT; Wiersma SR
    Drugs; 1991 Nov; 42(5):766-80. PubMed ID: 1723373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting.
    Brok J; Mavinkurve-Groothuis AMC; Drost J; Perotti D; Geller JI; Walz AL; Geoerger B; Pasqualini C; Verschuur A; Polanco A; Jones KP; van den Heuvel-Eibrink M; Graf N; Spreafico F
    Eur J Cancer; 2021 Feb; 144():113-122. PubMed ID: 33341445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-Gaussian model for apparent diffusion coefficient histogram analysis of Wilms' tumour subtype and response to chemotherapy.
    Hales PW; Olsen ØE; Sebire NJ; Pritchard-Jones K; Clark CA
    NMR Biomed; 2015 Aug; 28(8):948-57. PubMed ID: 26058670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
    Stefanowicz J; Sierota D; Balcerska A; Stoba C
    Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
    Hontecillas-Prieto L; Garcia-Dominguez DJ; Vaca DP; Garcia-Mejias R; Marcilla D; Ramirez-Villar GL; Saez C; de Álava E
    Oncotarget; 2017 Feb; 8(7):11173-11186. PubMed ID: 28061436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
    Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
    Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological parameters and prognostic relevance of miR-21 and PTEN expression in Wilms' tumor.
    Cui M; Liu W; Zhang L; Guo F; Liu Y; Chen F; Liu T; Ma R; Wu R
    J Pediatr Surg; 2017 Aug; 52(8):1348-1354. PubMed ID: 28040201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.
    Tretiakova M; Turkyilmaz M; Grushko T; Kocherginsky M; Rubin C; Teh B; Yang XJ
    J Clin Pathol; 2006 Dec; 59(12):1272-7. PubMed ID: 16556665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
    Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
    Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.